Maryland Patent of the Month – June 2024

Psomagen, Inc. has pioneered a transformative method for single molecule sequencing, addressing a fundamental challenge in the field: the imbalance in sequencing overrepresented and underrepresented nucleic acid targets. Traditional high throughput sequencing often results in the repeated sequencing of dominant targets, thereby obscuring rare molecules and skewing data.

The innovation hinges on the use of unique molecular identifiers (UMIs), which are sequences of random nucleotides that tag each nucleic acid molecule uniquely. By preparing UMI-based molecules that target specific nucleic acid sequences, Psomagen’s method ensures each target region is sequenced accurately. The process involves generating tagged nucleic acid molecules through both PCR-amplified and PCR-independent methods, enhancing the diversity and accuracy of the sequencing.

A critical aspect of this method is its ability to compare different UMI regions in real-time during sequencing. This comparison allows for the identification of matching sequences and the immediate cessation of further sequencing of those molecules. This approach not only conserves sequencing resources but also focuses efforts on underrepresented sequences, providing a more comprehensive and balanced dataset.

Psomagen’s method includes a mechanism for setting limits on the number of sequences generated for each target. This controlled sequencing ensures that even low-abundance molecules are adequately represented in the results, facilitating more precise detection and quantification of various nucleic acids, including those related to microorganisms, antibiotic resistance, and viral genes.

This advanced sequencing technique aims to revolutionize genomic research by offering improved accuracy, efficiency, and depth of analysis, particularly in complex biological samples where traditional methods fall short. Psomagen’s method represents a significant leap forward in the quest for comprehensive and balanced genomic data.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts